MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1161/hypertensionaha.125.24648

Медицинская библиотека · Hypertension (Dallas, Tex. : 1979) · 2025

Nationwide, Pragmatic, Direct-to-Patient Primary Aldosteronism Testing Program.

Brown Jenifer M, Tsai Laura C, Abel Eva E, Ferrebus Arnaldo, Moore Anna E, Niebuhr Yvonne M, Bacare Bassil, Honzel Brooke, Milks Julia, Foote Kristen, Newman Andrew J, Parksook Wasita W, Vaidya Anand

СтатьяПоддержка исследования: вне правительства СШАПоддержка NIH: внешняя программаПеревод в очереди

Аннотация

BACKGROUND

Primary aldosteronism, an endocrinopathy present in ≥10% to 25% of patients with hypertension, confers excess cardiovascular risk that can be mitigated with aldosterone-directed therapy. However, only 2% of eligible patients undergo guideline-recommended screening. This study aimed to bypass clinical inertia and identify people with primary aldosteronism using pragmatic, direct-to-patient testing.

METHODS

Hypertensive adults were recruited via online platforms and underwent virtual consent and local phlebotomy. Using a standardized diagnostic algorithm, laboratory results with interpretations were communicated to patients and primary care providers. Follow-up was ascertained at 6 to 12 months. The primary outcome was the frequency of a positive test for primary aldosteronism. Secondary outcomes included follow-up primary aldosteronism testing and implementation of aldosterone-targeted therapies.

RESULTS

The study population (N=694) had a mean age of 63.3±11.3 years, was 52.2% female, and hailed from 41 US states. Overall, 25.4% had a positive test for primary aldosteronism. Sleep apnea, resistant hypertension, and hypokalemia were the most common testing indications, with 55.2% of participants having ≥2 indications. Over half of participants (57%) were already under endocrinology, cardiology, or nephrology care, yet had not been tested. In longitudinal follow-up of participants with a positive result, 25.5% had additional testing, 13.7% were started on aldosterone-targeted therapy (mineralocorticoid receptor antagonist or adrenalectomy), and 24.5% reported improved blood pressure control.

CONCLUSIONS

Pragmatic, direct-to-patient testing, and simplified results interpretation is a feasible, scalable method to increase primary aldosteronism diagnoses and implementation of aldosterone-targeted therapies. Given that new hypertension guidelines recommend primary aldosteronism screening in all hypertensive people, practical approaches to test, interpret, and implement results will be essential.

Для цитирования: Brown Jenifer M, Tsai Laura C, Abel Eva E, Ferrebus Arnaldo, Moore Anna E, Niebuhr Yvonne M, Bacare Bassil, Honzel Brooke, Milks Julia, Foote Kristen, Newman Andrew J, Parksook Wasita W, Vaidya Anand. Nationwide, Pragmatic, Direct-to-Patient Primary Aldosteronism Testing Program.. Hypertension (Dallas, Tex. : 1979). 2025. DOI: 10.1161/hypertensionaha.125.24648.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.